Bulletin
Investor Alert

London Markets Open in:

Intercept Pharmaceuticals Inc.

NAS: ICPT

GO
/marketstate/country/us

After Hours

/zigman2/quotes/202434567/composite

$

43.37

Change

-0.68 -1.54%

Volume

Volume 9,858

Jul 8, 2020, 7:57 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/202434567/composite

Previous close

$ 45.37

$ 44.05

Change

-1.32 -2.91%

Day low

Day high

$43.00

$45.56

Open
Open: 45.56

52 week low

52 week high

$43.00

$125.00

Open

Market cap

$1.49B

Average volume

1.03M

P/E ratio

N/A

Rev. per Employee

$372,265

EPS

-10.72

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/icpt

MarketWatch News on ICPT

  1. Biogen Submits Troubled Alzheimer’s Drug for FDA Approval

    12:07 p.m. July 8, 2020

    - Barron's Online

  2. Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why.

    11:53 a.m. June 30, 2020

    - Barron's Online

  3. Intercept Pharmaceuticals downgraded to market perform at BMO Capital

    9:07 a.m. June 30, 2020

    - Tomi Kilgore

  4. Intercept Pharmaceuticals stock price target cut to $97 from $158 at B. Riley FBR

    7:53 a.m. June 30, 2020

    - Tomi Kilgore

  5. Intercept Pharmaceuticals stock price target cut to $50 from $89 at SVB Leerink

    6:11 a.m. June 30, 2020

    - Tomi Kilgore

  6. Intercept Shares Tumble on NASH Disappointment

    4:05 p.m. June 29, 2020

    - Barron's Online

  7. Intercept's stock plunges 35% premarket after receiving CRL from FDA for treatment of fibrosis due to NASH

    7:17 a.m. June 29, 2020

    - Tomi Kilgore

  8. Intercept Pharmaceuticals receives FDA letter for its treatment for fibrosis due to NASH

    7:15 a.m. June 29, 2020

    - Ciara Linnane

  9. Intercept Pharmaceuticals shares slide 35% premarket

    7:15 a.m. June 29, 2020

    - Ciara Linnane

  10. Intercept Pharmaceuticals started at outperform with $107 stock price target at BMO Capital

    8:35 a.m. June 5, 2020

    - Tomi Kilgore

  11. Coronavirus Is Bad — and Good — for Biotech Stocks

    5:52 p.m. March 10, 2020

    - Barron's Online

  12. Intercept Pharmaceuticals maintained as buy with $165 price target at Canaccord

    1:55 p.m. Dec. 13, 2019

    - Ciara Linnane

  13. Intercept Pharmaceuticals started at buy with $165 stock price target at Canaccord Genuity

    2:58 p.m. Dec. 2, 2019

    - Tomi Kilgore

  14. 5 Big Pharma Showdowns to Watch

    5:00 a.m. Aug. 12, 2019

    - Barron's Online

  15. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/icpt

Other News on ICPT

  1. Intercept Slumps as the FDA Issues CRL to NASH Candidate

    10:29 a.m. June 30, 2020

    - Zacks.com

  2. Company News for Jun 30, 2020

    9:35 a.m. June 30, 2020

    - Zacks.com

  3. Needham Thinks Intercept Pharma’s Stock is Going to Recover

    6:46 a.m. June 30, 2020

    - SmarterAnalyst

  4. ICPT, WKHS, HRTX and BLNK among midday movers

    12:41 p.m. June 29, 2020

    - Seeking Alpha

  5. What This FDA Update Means for Intercept Pharma

    8:05 a.m. June 29, 2020

    - 247WallSt.com

  6. Intercept down big on FDA rejection of obeticholic acid in NASH

    7:40 a.m. June 29, 2020

    - Seeking Alpha

  7. Genfit: Beaten Down But Not Dead

    9:55 p.m. June 18, 2020

    - Seeking Alpha

  8. New kid on the block in race for NASH drug

    5:34 p.m. June 15, 2020

    - Seeking Alpha

  9. Many 'Ifs' Surrounding Viking Therapeutics

    3:19 p.m. June 15, 2020

    - GuruFocus.com

  10. Loading more headlines...
/news/pressrelease/company/us/icpt

Press Releases on ICPT

  1. Non-alcoholic Steatohepatitis Market Set for Rapid Growth and Trend, by 2025

    11:32 a.m. June 10, 2020

    - HTF Market Intelligence

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.